期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease 被引量:2
1
作者 Eun Hye Oh Dae-Hyun Ko +12 位作者 Hyungil Seo kiju chang Gwang-Un Kim Eun Mi Song Myeongsook Seo Ho-Su Lee Sung Wook Hwang Dong-Hoon Yang Byong Duk Ye Jeong-Sik Byeon Seung-Jae Myung Suk-Kyun Yang Sang Hyoung Park 《World Journal of Gastroenterology》 SCIE CAS 2017年第8期1489-1496,共8页
To investigate the clinical implications of infliximab trough levels (IFX-TLs) and antibodies to infliximab (ATI) levels in Crohn’s disease (CD) patients in Asian countries.METHODSIFX-TL and ATI level were measured u... To investigate the clinical implications of infliximab trough levels (IFX-TLs) and antibodies to infliximab (ATI) levels in Crohn’s disease (CD) patients in Asian countries.METHODSIFX-TL and ATI level were measured using prospectively collected samples obtained with informed consent from CD patients being treated at Asan Medical Center, South Korea. We analyzed the correlations between IFX-TLs/ATI levels and the clinical activity of CD (quiescent vs active disease) based on the CD activity index, C-reactive protein level, and physician’s judgment of patients’ clinical status at enrollment. The impact of concomitant immunomodulators was also investigated.RESULTSThis study enrolled 138 patients with CD (84 with quiescent and 54 with active disease). In patients with quiescent and active diseases, the median IFX-TLs were 1.423 μg/mL and 0.163 μg/mL, respectively (P < 0.001) and the median ATI levels were 8.064 AU/mL and 11.209 AU/mL, respectively (P < 0.001). In the ATI-negative and -positive groups, the median IFX-TLs were 1.415 μg/mL and 0.141 μg/mL, respectively (P < 0.001). In patients with and without concomitant immunomodulator use, there were no differences in IFX-TLs (0.632 μg/mL and 1.150 μg/mL, respectively; P = 0.274) or ATI levels (8.655 AU/mL and 9.017 AU/mL, respectively; P = 0.083).CONCLUSIONIFX-TL/ATI levels were well correlated with the clinical activity in South Korean CD patients. Our findings support the usefulness of IFX-TLs/ATI levels in treating CD patients receiving IFX in clinical practice. 展开更多
关键词 INFLIXIMAB Drug effect ANTIBODY Crohn’s disease Drug monitoring
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部